Why CRISPR Therapeutics Stock Is Sinking Today
Shares of the gene-editing titan CRISPR Therapeutics (NASDAQ: CRSP) are seemingly in for a bad day. The biotech's stock dropped by nearly 10% in premarket trading today in response to an early look at phase 1 trial results for its blood cancer candidate CTX110.
CRISPR Therapeutics announced that this off-the-shelf CAR-T cell therapy produced a 58% overall response rate and a 38% complete response rate (no detectable signs of cancer) in a cohort of patients with large B-cell lymphoma treated with a single dose of CTX110. Equally important, the company noted that the observed side effects from the therapy were generally mild in nature.
Image source: Getty Images.
Source Fool.com
